Objective: To describe (1) sensitivity/specificity of physical examination to correctly diagnose a prolapsed vaginal mass as benign, (2) success rate for transvaginal myomectomy, (3) risk of associated malignancy. Design: A retrospective cohort study. Materials and Methods: Consecutive patients evaluated at the LAC + USC Medical Center from March 2007 to June 2012 with a diagnosis, including prolapsed leiomyoma, were reviewed. Medical records were reviewed for demographic information, clinical findings, histology reports, and clinical outcomes. Results: Two hundred twenty-six cases were identified. Mean age was 44.2 (-9.1) years and 83.6% of cases were premenopausal. The most common symptom was bleeding (79.2%); 15% of the women were asymptomatic. Most were successfully treated with transvaginal myomectomy, although 14 (6.2%) required urgent hysterectomy. There were no cases of uterine infection before intervention; delay of treatment resulted in acute bleeding in 2 of 18 women. Subsequent hysterectomy was performed in 10.9% of women and was more common in women with additional leiomyomata, compared to those without (24.6% vs. 3.4%, p = 0.004). The positive predictive value of examination to predict malignancy was 21.4%. The sensitivity and specificity of examination to detect malignancy were 42.8% and 95.0%, respectively. Concomitant endometrial hyperplasia or cancer was found in 4.2% of women sampled. Conclusions: The sensitivity of physical examination to exclude malignancy in prolapsing lesions is poor. Delayed management of prolapsed leiomyomata appears safe, but carries some risk of bleeding. The preferred treatment is transvaginal myomectomy, avoiding further surgery in 89.1% of women. Concomitant endometrial sampling should be considered to evaluate for endometrial hyperplasia or malignancy. ( J GYNECOL SURG 31:205)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.